MedWatch

Bavarian management shocked by phase III flop

Bavarian Nordic’s pivotal phase III study with the candidate Prostvac has turned out to be a flop. Surprising and shocking, says the CEO.

Last week was not an easy week for the Danish biotech company Bavarian Nordic after the management announced the termination of the pivotal phase III study with the company’s prostate cancer vaccine, Prostvac, following the last interim analysis of data.

The independent data monitoring committee firmly concluded that it makes no sense to continue the study and recommended to pull the plug. The tough announcement was like a cold douche for Bavarian Nordic’s management.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier